NervGen Pharma Cash Per Share vs. Debt To Equity
| NGENF Stock | USD 1.85 0.06 3.35% |
For NervGen Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NervGen Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NervGen Pharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NervGen Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NervGen Pharma Corp over time as well as its relative position and ranking within its peers.
NervGen |
NervGen Pharma Corp Debt To Equity vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NervGen Pharma's current stock value. Our valuation model uses many indicators to compare NervGen Pharma value to that of its competitors to determine the firm's financial worth. NervGen Pharma Corp is considered to be number one stock in cash per share category among its peers. It also is considered to be number one stock in debt to equity category among its peers fabricating about 0.16 of Debt To Equity per Cash Per Share. The ratio of Cash Per Share to Debt To Equity for NervGen Pharma Corp is roughly 6.25 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NervGen Pharma's earnings, one of the primary drivers of an investment's value.NervGen Debt To Equity vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
NervGen Pharma |
| = | 0.20 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
NervGen Pharma |
| = | 0.03 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
NervGen Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NervGen Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NervGen Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NervGen Pharma's change in net profit over the period of time. It can combine multiple indicators of NervGen Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.
NervGen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NervGen Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NervGen Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NervGen Pharma's important profitability drivers and their relationship over time.
Use NervGen Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NervGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NervGen Pharma will appreciate offsetting losses from the drop in the long position's value.NervGen Pharma Pair Trading
NervGen Pharma Corp Pair Trading Analysis
The ability to find closely correlated positions to NervGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NervGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NervGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NervGen Pharma Corp to buy it.
The correlation of NervGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NervGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NervGen Pharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NervGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NervGen Pharma position
In addition to having NervGen Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Funds Thematic Idea Now
Healthcare Funds
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in NervGen OTC Stock
To fully project NervGen Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of NervGen Pharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include NervGen Pharma's income statement, its balance sheet, and the statement of cash flows.